Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Works matching IS 11727047 AND DT 2024 AND VI 38 AND IP 10
Results: 7
1
2
New and Emerging Drug and Gene Therapies for Friedreich Ataxia.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 791, doi. 10.1007/s40263-024-01113-z
- By:
- Publication type:
- Article
3
Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 807, doi. 10.1007/s40263-024-01112-0
- By:
- Publication type:
- Article
4
Effects of Trazodone on Sleep: A Systematic Review and Meta-analysis.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 753, doi. 10.1007/s40263-024-01110-2
- By:
- Publication type:
- Article
5
Incident Benzodiazepine and Z-Drug Use and Subsequent Risk of Serious Infections.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 827, doi. 10.1007/s40263-024-01108-w
- By:
- Publication type:
- Article
6
Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 819, doi. 10.1007/s40263-024-01104-0
- By:
- Publication type:
- Article
7
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
- Published in:
- CNS Drugs, 2024, v. 38, n. 10, p. 771, doi. 10.1007/s40263-024-01101-3
- By:
- Publication type:
- Article